

Nanoscale

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

Enhanced MRI relaxivity of aquated Gd^{3+} ions by carboxyphenylated water-dispersed graphene nanoribbons

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Ayrat Gizzatov,^a Vazrik Keshishian,^a Adem Guven,^a Ayrat M. Dimiev,^a Feifei Qu,^b Raja Muthupillai,^b Paolo Decuzzi,^c Robert G. Bryant,^d James M. Tour,^{*a} and Lon J. Wilson^{*a}

The present study demonstrates that highly water-dispersed graphene nanoribbons dispersed by carboxyphenylated substituents and conjugated to aquated Gd^{3+} ions can serve as a high-performance contrast agent (CA) for applications in T_1 - and T_2 -weighted magnetic resonance imaging (MRI) with relaxivity ($r_{1,2}$) values outperforming currently-available clinical CAs by up to 16 times for r_1 and 21 times for r_2 .

Since the discovery of graphene by Geim and Novoselov in 2004, extensive research has been performed in diverse fields of science, engineering, and medicine to take advantage of its unique properties.¹⁻⁴ Properties such as excellent electrical conductivity, thermal stability, mechanical strength, and other unusual chemical and optical properties have made graphene an extensively studied material for composites, transistors, biosensors, nanomedicines, and many other types of materials requiring the exceptional properties of graphene and graphene-based materials.

Magnetic resonance imaging (MRI) is one of the most powerful imaging tools in the clinic for non-invasive diagnostics.⁵ Many of its capabilities depend on the use of chemical contrast agents (CAs), which are employed to enhance local signal intensity to improve diagnostic confidence.⁶

Image contrast in MRI arises largely from differences in water-proton spin-lattice relaxation time (T_1) and spin-spin relaxation times (T_2). Thus, chemical CAs are categorized as either T_1 or T_2 agents based on the efficiency of changing T_1 or T_2 in the observable water pool. T_1 CAs are mainly Gd^{3+} -based and provide brighter images, whereas T_2 CAs produce darker images and are usually superparamagnetic iron oxide (SPIO) nanoparticles.⁷ Relaxivity ($r_{1,2}$) is the parameter of CAs which defines their efficacy and is the relaxation rate enhancement in $1/(\text{mM} \times \text{s})$ of the CA.⁸

There has been extensive effort to develop new CAs with increased relaxivities using small Gd^{3+} -ion chelates, dendrimers, polymers, micelles, and various nanostructures.⁹⁻¹⁶ In recent years, a great diversity of nanostructure-based CAs have been developed

which exhibit high relaxivity. In particular, honeycomb carbon nanostructures such as gadofullerenes,¹⁷⁻¹⁹ gadonanotubes,¹⁴ and gadographene²⁰ have shown the highest relaxivity values for the Gd^{3+} ion. In this work we report a new type of carbon nanostructure-based CA, with Gd^{3+} ions conjugated to covalently functionalized highly water-dispersed graphene nanoribbons (Gd/GNRs) to produce greatly enhanced r_1 and r_2 values ($70 \pm 6 \text{ mM}^{-1}\text{s}^{-1}$ and $108 \pm 9 \text{ mM}^{-1}\text{s}^{-1}$, respectively) at 1.41 T and 37 °C. These values are up to 16 times and 21 times higher for r_1 and r_2 respectively, when compared to clinically available Magnevist® CA with $r_1 \approx 4 \text{ mM}^{-1}\text{s}^{-1}$ and $r_2 \approx 5 \text{ mM}^{-1}\text{s}^{-1}$ at 1.5 T.¹¹ Unlike the recently reported and related gadographene CA²⁰, the present Gd/GNR CAs do not require a surfactant to suspend them in water and biological media.

To prepare the Gd/GNRs, synthesis of the GNRs with a width of 125 – 280 nm, thickness of 7 – 15 nm, and length of up to 20 μm was achieved first by melting K/Na alloy over multi-walled carbon nanotubes (MWCNTs) under vacuum (0.05 Torr),²¹ unlike the preparation of GNRs that uses KMnO_4 .^{22,23} The GNRs were then repetitively derivatized with *p*-carboxyphenyldiazonium salt to make them highly water dispersed (4.7 mg mL^{-1}) and to provide carboxylic acid groups for Gd^{3+} coordination.²⁴ Next, an aqueous solution of GdCl_3 (30 mg in 3 mL) was added to an aqueous dispersion (10 mL) of GNRs (10 mg) and the mixture was sonicated in a bath for 15 min. The mixture was then vacuum filtered using an Anapore™ inorganic membrane disc with a pore size of 0.02 μm (Anodisc™) and thoroughly washed with DI water multiple times until no Gd^{3+} ions were present in the filtrate (confirmed by ICP-OES). The black solid collected on the filter (Gd/GNRs) was then characterized using transmission electron microscopy (TEM) (Fig. 1) equipped with electron dispersion spectroscopy (EDS), X-ray photoelectron spectroscopy (XPS), inductively-coupled plasma optical emission spectrometry (ICP-OES), a benchtop relaxometer (Bruker Minispec) operating at 1.41 T and 37 °C with a 5-mm probe, a clinical 1.5 T MRI scanner (Philips Achieva), and a fast field cycling nuclear magnetic resonance (NMR) spectrometer FFC-200 (Stellar s. r. l., Mede, Italy).




Fig. 1 TEM images of the Gd/GNRs sample.

To better understand the nature and presence of the Gd^{3+} ions on the surface of the GNRs, TEM equipped with an EDS was used. The top row of Figure 2 shows TEM images of the Gd/GNRs (Fig. 2a) and




Fig. 2 TEM images of a) Gd/GNRs and b) GNRs. Electron dispersion spectroscopy (EDS) - TEM mapping for Gd^{3+} and Cu^{2+} of c) Gd/GNRs and d) GNRs (mapping areas designated by dotted white lines), and e) EDS spectra of the Gd/GNRs and GNRs (scale bars = 600 nm).

GNRs (Fig. 2b) with corresponding EDS mappings (mapping areas designated by dotted white lines) on the bottom row for Gd^{3+} and Cu^{2+} of the Gd/GNR sample (Fig. 2c) and the GNR sample (Fig. 2d). Cu^{2+} and Gd^{3+} -ion mapping are shown together due to the overlap of the spectral peaks of these two elements; the trace of the Cu^{2+} -ion signal is due to the copper grid TEM sample holder. From the EDS images it is clear that the Gd/GNR sample surface is covered with Gd^{3+} ions (white spots) (Fig. 2c), whereas the GNR sample is not (Fig. 2d). Coverage of the GNR surface with Gd^{3+} ions was produced by coordination of the ions to the carboxylate groups of the GNRs. The EDS spectra (Fig. 2e) of the Gd/GNRs also show the presence of Gd^{3+} ions (≈ 1 KeV and ≈ 8 KeV) with traces of Cl^- ion (≈ 3 KeV) coming from the $GdCl_3$ used to prepare the Gd/GNRs.

XPS data (Fig. 3) also provides evidence for the presence of Gd^{3+} on the surface of Gd/GNR sample. The photoelectron peak corresponding to the Gd^{3+} ion 4d level was observed at ~ 141 eV for a Gd/GNR sample, whereas for a GNR sample no peak was observed in the region. Peaks for Si at 153 eV (Si_{2s}) and 102 eV (Si_{2p}) are due to contamination from the Pyrex ampule during synthesis of the GNRs from MWCNTs. Na^+ ion (~ 1071 and 496 eV) was introduced to the sample during the functionalization step.²⁴




Fig. 3 XPS data for the GNR and Gd/GNR samples.

The amount of Gd^{3+} in a solid Gd/GNR sample was determined to be 1.5 ± 0.4 % w/w by ICP-OES. For the determination, a known amount of Gd/GNRs (0.2 – 0.5 mg) was carefully heated in 36 % w/w $HClO_3$ (1 – 2 mL) to completely remove any remaining carbonaceous material and then reconstituted in 5 mL 2 % HNO_3 for ICP –OES analysis.

Relaxation times T_1 and T_2 were measured using a Brüker Minispec operating at 1.41 T and 37 °C. Gadolinium concentrations were determined using ICP-OES and a linear relation between relaxation rate and concentration was found (Fig. S1) with slopes of 70 ± 6 $mM^{-1} s^{-1}$ for r_1 and 108 ± 9 $mM^{-1} s^{-1}$ for r_2 ($n = 4$). T_1 was also measured as a function of magnetic field strength using a Stellar Spin Master field cycling spectrometer (Mede, Italy). Samples were contained in 10 mm tubes at 25 °C.




Fig. 4 a) T_1 -weighted MRI inversion recovery phantom images acquired at different inversion times (TI) for the GNR, Gd/GNR samples in aqueous dispersions and H_2O at 1.5 T. b) T_2 -weighted MRI spin-echo phantom images acquired at different echo times (TE) for the GNR, Gd/GNR samples in aqueous dispersions and H_2O at 1.5 T.

The effectiveness of the Gd/GNRs as a T_1 and T_2 CA was assessed via a 1.5 T MRI clinical scanner. From the T_1 -weighted phantom images (Fig. 4a) obtained at different inversion times (TI) for the same amount of (0.225 mg/mL) aqueous dispersion of GNRs, Gd/GNRs (~1.7 % Gd w/w) and H_2O samples it is clear that there is great contrast enhancement for the Gd/GNR sample, when compared to GNRs and H_2O . Similarly, from the T_2 -weighted phantom images (Fig. 4b) acquired at different echo times (TE) for the same samples, there is clearly observable contrast enhancement for the Gd/GNR sample when compared to GNRs and H_2O . No contrast enhancement for the GNRs alone when compared to H_2O is presented in order to show that there is no relaxivity contribution due to possible trace metal impurities. The images presented in Figure 4 show the efficacy of the Gd/GNRs as a CA for T_1 - and T_2 -weighted imaging.

To better understand the binding nature of Gd^{3+} to the GNRs, strong acid (1 M HCl), strong base (1 M NaOH), and DI water washings were performed on the Gd/GNR sample. To determine the results for a known amount of Gd/GNRs, samples were dispersed in 1 M HCl, 1 M NaOH, and deionized water and the dispersions were then sonicated for 10 min before filtration through 0.22 μm glass syringe filters. Filtrates were analyzed via ICP-OES for the presence of Gd^{3+} . It was found that 1 M HCl removes the Gd^{3+} ions from the surface of the GNRs. Repeating this procedure with 1 M NaOH or DI water did not remove any detectable Gd^{3+} . These results support the assumption that the Gd^{3+} ions are coordinated to carboxylate groups present on the surface of the functionalized GNRs, since only protonation of these groups by acid removes the Gd^{3+} ions.

To check for the physiological stability of the Gd^{3+} ions in the Gd/GNRs, 1X phosphate buffered saline (PBS) and fetal bovine serum (FBS) *in vitro* challenges were performed. In two separate experiments, a Gd/GNR sample was challenged for 24 h at 37 $^{\circ}C$ in 1X PBS and FBS. The resulting dispersions were filtered through a 0.22 μm glass syringe filter and the filtrates were analysed for Gd^{3+} content




Fig. 5 The spin-lattice-relaxation normalized to Gd^{3+} concentration as a function of magnetic field strength reported as the 1H Larmor frequency at 0.01 – 20 MHz and 25 $^{\circ}C$ for water protons in an aqueous suspension of the Gd/GNRs.

with ICP-OES. 1X PBS challenge did not produce any Gd^{3+} ion loss, while the FBS challenge resulted in a loss of ca. $50 \pm 10\%$ ($n = 3$) of the Gd^{3+} ions from multiple samples functionalized at different times. After the first FBS challenge, the same sample did not lose additional Gd^{3+} ions with subsequent challenges. In the case of PBS, no Gd^{3+} loss was observed, since no strongly chelating agents or ions capable of replacing Gd^{3+} are present in PBS. For FBS, the proteins present are good chelating agents and are apparently capable of removing loosely bound Gd^{3+} ions from the surface of the Gd/GNRs. Neither of the challenges resulted in measurable changes in r_1 or r_2 for the coordinated to GNRs Gd^{3+} ion. Thus, due to the material nature of the Gd/GNRs, there appear to be different kinds of coordination sites present, and after the first FBS challenge the same sample becomes stable to subsequent FBS challenges at physiological pH and temperature.

The relaxation rate constants for the Gd/GNRs ($[Gd] = 0.0345$ mM) sample (Fig. 5) are large and demonstrate that the Gd^{3+} ion first coordination sphere waters exchange rapidly with bulk water. The low field relaxation rate is essentially constant, but with increasing field there is a decrease followed by an increase and a maximum, which is not observed in the present experiments. This relaxation dispersion profile is characteristic of a slowly rotating Gd^{3+} -ion complex.^{25,26} The increase in relaxation rates at high field derives from the magnetic field dependence of the electron-spin relaxation rate constant which makes the effective correlation time for the electron-nuclear coupling a function of magnetic field. Thus, the nuclear spin-relaxation properties are decoupled from the rotational and exchange dynamics of the Gd^{3+} complex throughout the magnetic field range studied here. The dominance of electron spin relaxation is the rule in slowly rotating Gd^{3+} complexes.

Contributions from non-metal radicals, which are common adjuncts of polynuclear aromatic preparations would generally induce nuclear spin relaxation by outer sphere or translational diffusive motions of the water in the vicinity of the radical. The shape of the relaxation dispersion profile from this class of dynamics is

characteristically a constant relaxation rate at low field and a decrease in relaxation rate constant at high field without the dramatic increase observed in Figure 5. It is also possible that magnetic domains may form in particulate systems that, in some instances, may present a relaxation dispersion profile similar to that shown in Figure 5.²⁷ However, we have no evidence that such organization occurs in the present preparations.

The above results demonstrate that Gd³⁺ ions in Gd/GNRs are coordinated to the carboxylate groups of the GNRs. The number of the Gd³⁺-ion coordination sites occupied by the carboxylate groups is unclear, even though the total coordination number for individual Gd³⁺ ions is normally 8 or 9.^{28,29} It is known that the r_1 relaxivity of a Gd³⁺-ion CA depends on many parameters, but the most dominant factors are the tumbling time, the water-exchange rate, and the number of available sites for water coordination.^{30,31} In our case, the large r_1 and r_2 relaxivity values are most likely due to a larger number of water coordination sites on the Gd³⁺ ion.

In conclusion, we have shown that surfactant-free carboxyphenylated water-dispersed graphene nanoribbons are capable of increasing r_1 to $70 \pm 6 \text{ mM}^{-1}\text{s}^{-1}$ and r_2 to $108 \pm 9 \text{ mM}^{-1}\text{s}^{-1}$ for Gd³⁺ ions coordinated to the carboxylate groups. These values are 16 and 21 times greater when compared to current clinically-available Gd³⁺-based T₁ CAs, and about the same as found for gadographene suspended with surfactant. Because the Gd/GNRs are lipophilic and stable to Gd³⁺-ion loss under physiological conditions (after one FBS challenge), they possibly can be safely used to internally label cells for MRI tracking *in vivo*, similar to other Gd³⁺-ion containing carbon nanostructures such as the gadofullerenes^{30,32} or the gadonanotubes.^{33,34} Of the four gadocarbon nanostructure labeling agents (gadofullerenes, gadonanotubes, gadographene, and Gd/GNRs), the much greater availability of the last three suggests that they might become the preferred cell labeling agents. Of these three, the covalently-functionalized Gd/GNRs could have advantages over the surfactant-wrapped nanostructures, especially if the surfactant wrapping is unstable to cell membrane transport during the cell labeling process. We are presently exploring this possibility.³⁵

A. Gizzatov, V. K., A. Guven, and L. J. W. acknowledge The Welch Foundation (C-0627) for partial support of this work, while A. M. D. and J. M. T. acknowledge the ONR (#00006766, N00014-09-1-1066), the AFOSR MURI (FA9550-12-1-0035), and the AFOSR (FA9550-09-1-0581).

Notes and references

^a Department of Chemistry, Richard E. Smalley Institute for Nanoscale Science and Technology, Rice University, 6100 Main Street, Houston, TX-77005, USA.

^b Department of Radiology, St. Luke's Episcopal Hospital, 6720 Bertner Avenue, MC 2-270, Houston, TX-77030-2697, USA.

^c Department of Translational Imaging, The Methodist Hospital Research Institute, 6560 Fannin St, Houston, TX-77030, USA

^d Department of Chemistry, University of Virginia, Charlottesville, VA-22904-4319, USA

† Electronic Supplementary Information (ESI) available: See DOI: 10.1039/c000000x/

- 1 K. S. Novoselov, A. K. Geim, S. V. Morozov, D. Jiang, Y. Zhang, S. V. Dubonos, I. V. Grigorieva, A. A. Firsov, *Science*, 2004, **306**, 666.
- 2 X. Huang, Z. Yin, S. Wu, X. Qi, Q. He, Q. Zhang, Q. Yan, F. Boey, H. Zhang, *Small*, 2011, **7**, 1876.
- 3 L. Feng, Z. Liu, *Nanomedicine*, 2011, **6**, 317.
- 4 F. Schwierz, *Nature Nanotech.*, 2010, **5**, 487.
- 5 P. Caravan, J. J. Ellison, T. J. McMurry, R. B. Lauffer, *Chem. Rev.*, 1999, **99**, 2293.
- 6 A. E. Merbach, E. Toth, *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*, John Wiley and Sons, Ltd: Chichester **2001**.
- 7 R. Weissleder, M. Papisov, *Rev. Magn. Reson. Med.*, 1992, **4**, 1.
- 8 S. Aime, M. Fasano, E. Terreno, *Chem. Soc. Rev.*, 1998, **27**, 19.
- 9 J. Tang, Y. Sheng, H. Hu, Y. Shen, *Prog. Polym. Sci.*, 2013, **38**, 462.
- 10 J. Kim, Y. Piao, T. Hyeon, *Chem. Soc. Rev.*, 2009, **38**, 372.
- 11 S. Langereis, Q. G. de Lussanet, M. H. P. van Genderen, W. H. Backes, E. W. Meijer, *Macromolecules*, 2004, **37**, 3084.
- 12 K. N. Raymond, V. C. Pierre, Next Generation, *Bioconjugate Chem.*, 2005, **16**, 3.
- 13 L. M. Manus, D. J. Mastarone, E. A. Waters, X. Q. Zhang, E. A. Schultz-Sikma, K. W. MacRenaris, D. Ho, T. J. Meade, *Nano Lett.*, 2010, **10**, 484.
- 14 B. Sitharaman, K. R. Kissell, K. B. Hartman, L. A. Tran, B. Baikalov, I. Rusakova, Y. Sun, H. A. Khant, S. J. Ludtke, W. Chiu, S. Laus, É. Tóth, L. Helm, A. E. Merbach, L. J. Wilson, *Chem. Commun.*, 2005, **31**, 3915.
- 15 M. Mikawa, H. Kato, M. Okumura, M. Narazaki, Y. Kanazawa, N. Miwa, H. Shinohara, *Bioconjugate Chem.*, 2001, **12**, 510.
- 16 C. Richard, B. T. Doan, J. C. Beloile, M. Bessodes, E. Toth, D. Sherman, *Nano Lett.*, 2008, **8**, 232.
- 17 H. Kato, Y. Kanazawa, M. Okumura, A. Taninaka, T. Yokawa, H. Shinohara, *J. Am. Chem. Soc.*, 2003, **125**, 4391.
- 18 C. Y. Shu, F. D. Corwin, J. F. Zhang, Z. J. Chen, J. E. Reid, M. H. Sun, W. Xu, J. H. Sim, C. R. Wang, P. P. Fatouros, A. R. Esker, H. W. Gibson, H. C. Dorn, *Bioconjugate Chem.*, 2009, **20**, 1186.
- 19 S. Laus, B. Sitharaman, E. Toth, R. D. Bolskar, L. Helm, L. J. Wilson, A. E. Merbach, *J. Phys. Chem. C*, 2007, **111**, 5633.
- 20 A. H. Hung, M. C. Duch, G. Parigi, M. W. Rotz, L. M. Manus, D. J. Mastarone, K. T. Dam, C. C. Gits, K. W. MacRenaris, C. Luchinat, M. C. Hersam, T. J. Meade, *J. Phys. Chem. C*, 2013, **117**, 16263.
- 21 D. V. Kosynkin, W. Lu, A. Sinitskii, G. Pera, Z. Sun, J. M. Tour, *ACS Nano*, 2011, **5**, 968.
- 22 D. V. Kosynkin, A. L. Higginbotham, A. Sinitskii, J. R. Lomeda, A. Dimiev, B. K. Price, J. M. Tour, *Nature*, 2009, **458**, 872.
- 23 B. S. Paratala, B. D. Jacobson, S. Kanakia, L. D. Francis, B. Sitharaman, *PLoS ONE*, 2012, **7**, e38185.
- 24 A. Gizzatov, A. Dimiev, Y. Mackeyev, J. M. Tour, L. J. Wilson, *Chem. Commun.*, 2012, **48**, 5602.
- 25 I. Solomon, *Phys. Rev.*, 1961, **99**, 842.
- 26 N. Bloembergen, L. O. Morgan, *J. Chem Phys.*, 1961, **34**, 842.
- 27 A. Roch, R. N. Muller, *J. Chem. Phys.*, 1999, **110**, 5403.
- 28 T. Kurisaki, T. Yamaguchi, T. Wakita, *J. Alloys. Comp.*, 1993, **192**, 293.
- 29 H. Kanno, H. Yokoyama, *Polyhedron*, 1996, **15**, 1437.
- 30 V. C. Pierre, M. Botta, K. N. A. Raymond, *J. Am. Chem. Soc.*, 2005, **127**, 504.

Journal Name

- 31 W. B. Tan, Y. Zhang, *Adv. Mater.*, 2005, **17**, 2375.
- 32 B. Sitharaman, L. A. Tran, Q. P. Pham, R. D. Bolskar, R. Muthupillai, S. D. Flamm, A. G. Mikos, L. J. Wilson, *Contrast Media Mol. Imaging*, 2007, **2**, 139.
- 33 L. A. Tran, R. Krishnamurthy, R. Muthupillai, M. G. Cabreira-Hansen, J. T. Willerson, E. C. Perin, L. J. Wilson, *Biomaterials*, 2010, **31**, 9482.
- 34 R. Sethi, Y. Mackeyev, L. J. Wilson, *Inorg. Chim. Acta*, 2012, **393**, 165.
- 35 S. J. Corr, A. Gizzatov, B. T. Cisneros, L. J. Wilson, S. Curley, presented at 223rd ECS Meeting. Cytotoxicity and Biocompatibility of Highly Water-Soluble Graphene Nanoribbons Derivatized with *p*-Carboxyphenyldiazonium Salt, Toronto, Canada, May 12 - 17, **2013**.